相关实验视频
Updated: Mar 6, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
患者和护理人员对每周注射一次用于治疗生长激素缺乏症的注射器的偏好
Jing Voon Chen1, Bradley S Miller2,3, Nicky Kelepouris4
1Health Economics and Outcomes Research, Novo Nordisk Inc, Plainsboro, NJ 08536, USA.
Journal of the Endocrine Society
|March 5, 2026
概括
患者和护理人员在选择长效生长激素 (GH) 类似物 (LA-GHA) 治疗GH缺乏症 (GHD) 时优先考虑减少注射疼痛和更少的剂量. 使用方便和舒适性是治疗偏好的关键因素.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 患者报告的结果
背景情况:
- 长效生长激素 (GH) 模拟剂 (LA-GHA) 治疗为生长激素缺乏症 (GHD) 的每日注射提供了一个方便的替代方案.
- 了解患者和护理人员对LA-GHAs的偏好对于优化治疗选择和坚持治疗至关重要.
研究的目的:
- 确定影响LA-GHA治疗选择的关键注射和设备属性,在患有GHD的患者和他们的护理人员中.
- 为了比较不同LA-GHA个人资料的患者/护理人员偏好.
主要方法:
- 一项横截面研究,利用有针对性的文献综述和定性访谈来开发一个在线调查.
- 该调查包括一个离散选择实验,展示假设的LA-GHA设备特征.
- 参与者包括成年患者,儿童的照顾者,以及在美国被诊断患有GHD的青少年/照顾者双组.
主要成果:
- 注射后的疼痛 (27%),每次注射的注射数量 (23%),以及准备时间 (16%) 是最重要的LA-GHA属性.
- 类似于somapacitan-beco的治疗概况显示出最高的预测选择概率 (82%).
结论:
- 患者和护理人员的偏好强调减少注射疼痛和改善LA-GHAs的易用性.
- 基于这些偏好的共享决策可以提高GHD管理中的治疗坚持和临床结果.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
973
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
973
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
66
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
66
Insulin Formulations: Types and Delivery
893
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
893
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
352
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
352
Drug Dosing: Obese Patients
320
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320
Modified-Release Drug Delivery Systems: Rate-Programmed I
63
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
63

